Protocol Ledger

NCT05083923 · Phase III · COMPLETED

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

Interventional Phase III clinical trial protocol NCT05083923 sponsored by Biogen in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-18 Enrollment: 136 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05083923
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)136 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05083923
Protocol FieldVerified Registry Value
NCT IdentifierNCT05083923
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment136 participants (ACTUAL)
Registered Start Date2021-11-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI